-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug ...

SAN DIEGO -- AXS-12 (reboxetine), an investigational treatment for narcolepsy, reduced weekly cataplexy attacks and in some cases provided complete remission, the phase III SYMPHONY study showed. From ...

DUBLIN, May 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S. Food & Drug ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...

-Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care over all twice-nightly oxybates DUBLIN, Ireland, June 05, 2023 (GLOBE NEWSWIRE) -- Avadel ...

On October 16, 2024, LUMRYZ was additionally approved as a once-at-bedtime treatment for cataplexy or EDS in patients 7 years of age and older with narcolepsy. The FDA approval of LUMRYZ was supported ...

INDIANAPOLIS -- Extended-release sodium oxybate (Lumryz) taken once before bedtime was preferred by patients with narcolepsy over twice-nightly dosing and was generally well tolerated, according to ...